According to GlobalData, a leading data and analytics company, the nuclear imaging agents market in the Asia-Pacific region is projected to reach $1,105 million in 2034 driven by an aging population, rising chronic disease burden, and government healthcare investments
GlobalData’s report, “Nuclear Imaging Agents Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2036,” reveals that China made up to over half of the APAC nuclear imaging agents’ market in 2024, while Japan and India together comprised 23%.
Prerna Gupta, Medical Devices Analyst at GlobalData, comments: “An increasing disease burden and the move toward hybrid imaging systems are prompting steady, focused investment in nuclear diagnostics, leading manufacturers and service providers to prioritize tracer innovation to meet varied needs.”
Greater adoption of PET/CT and SPECT/CT agents is boosting diagnostic precision, streamlining workflows, and opening prospects for new tracers and integrated imaging offerings.
Shortage of trained staff, insufficient government health insurance in developing countries and the high cost of advanced treatments are some of the obstacles to the market growth in the APAC region.
Gupta concludes: “Increase in the number of private healthcare and diagnostic centers, better reimbursement policies, and targeted workforce training programs could enable more patients to access advanced therapies, supporting the market expansion.”